Surgical Stapler with Controlled Healing
Methods and devices are provided for promoting wound healing. In general, surgical staplers and staple components are provided having an effective amount of at least matrix metalloproteinase (MMP) inhibitor being effective to prevent MMP-mediated extracellular matrix degeneration during wound healing in tissue.
1 . A staple cartridge assembly for use with a surgical stapler, comprising:
a cartridge body having a plurality of staple cavities, each staple cavity having one of a plurality of surgical staples disposed therein; and
wherein at least one of a portion of the plurality of staples include an effective amount of at least one matrix metalloproteinase (MMP) inhibitor being effective to prevent at least one of MMP-mediated extracellular matrix degeneration and inflammation during wound healing in the tissue in a predetermined manner.
2 . The assembly of claim 1 , wherein the at least one MMP inhibitor is disposed on at least a portion of the plurality of staples.
3 . The assembly of claim 1 , further comprising a biocompatible adjunct material releasably retained on the cartridge body and configured to be delivered to tissue by deployment of the staples in the cartridge body, wherein an effective amount of at least one MMP inhibitor is disposed within and releasable from the adjunct material.
4 . The assembly of claim 1 , wherein the MMP inhibitor is configured to inhibit one or more of MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP23B, MMP25, MMP25, MMP26, MMP27, and MMP28.
5 . The assembly of claim 5 , wherein the MMP inhibitor is configured to inhibit a collagenase, a gelatinase, a stromelysin, or a membrane-type MMP.
6 . The assembly of claim 1 , wherein the MMP inhibitor is configured to inhibit MMP9.
7 . The assembly of claim 1 , wherein the MMP inhibitor is a tissue inhibitor of metalloproteinase (TIMP).
8 . The assembly of claim 1 , wherein the TIMP is at least one of TIMP1, TIMP2, TIMP3 and TIMP4.
9 . The assembly of claim 1 , wherein the MMP inhibitor is one or more of a hydroxymate, carboxylate, carbamoylphosphonate, hydroxyurea, hydrazine, β-lactam, squaric acid, nitrogenous ligand, thiol, and phosphinyl.
10 . The assembly of claim 1 , wherein the MMP inhibitor is configured to prevent inflammation-causing cells from being attracted to the tissue following deployment of the staples.
11 . A method for temporarily inhibiting wound healing at a surgical site immediately following surgical stapling of tissue by a surgical stapler, comprising:
engaging tissue between a cartridge assembly and an anvil of an end effector; and
actuating the end effector to eject staples from the cartridge assembly into the tissue,
wherein at least one of a portion of the plurality of staples and the adjunct material include an effective amount of at least one matrix metalloproteinase (MMP) inhibitor, and wherein release of the MMP inhibitor prevents MMP-mediated extracellular matrix degeneration during wound healing in the tissue in a predetermined manner.
12 . The method of claim 11 , wherein the at least MMP inhibitor is disposed on at least a portion of the plurality of staples.
13 . The method of claim 11 , wherein the MMP inhibitor inhibits at least one of MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP23B, MMP25, MMP25, MMP26, MMP27, and MMP28.
14 . The method of claim 13 , wherein the MMP inhibitor inhibits at least one of a collagenase, a gelatinase, a stromelysin, and a membrane-type MMP.
15 . The method of claim 13 , wherein the MMP inhibitor inhibits MMP9.
16 . The method of claim 13 , wherein the MMP inhibitor is a tissue inhibitor of metalloproteinase (TIMP).
17 . The method of claim 16 , wherein the TIMP is at least one of TIMP1, TIMP2, TIMP3 and TIMP4.
18 . The method of claim 13 , wherein the MMP inhibitor is at least one of a hydroxymate, carboxylate, carbamoylphosphonate, hydroxyurea, hydrazine, β-lactam, squaric acid, nitrogenous ligand, thiol, and phosphinyl.
19 . The method of claim 13 , wherein the MMP inhibitor prevents inflammation-causing cells from being attracted to the tissue following deployment of the staples.